Visudyne sustains vision benefit after three years:
This article was originally published in Clinica
Executive Summary
QLT and Novartis say that three-year follow-up data is now available to support their photodynamic therapy for age-related macular degeneration, the leading cause of blindness in people over the age of 50. The average visual acuity of patients who received the therapy, Visudyne, remained stable between the 24th and 36th month of follow-up, while the number of Visudyne treatments required continued to decrease, says QLT, of Vancouver, British Columbia. All the patients studied had predominantly classic subfoveal choroidal neovascularisation - the indication for which Visudyne is currently approved in the US and Europe.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.